SCOTUS' Mifepristone Decision Sets High Bar For US FDA Suits

Agency Authority Still Faces Risks

The unanimous decision that the Alliance for Hippocratic Medicine lacks standing to challenge the FDA’s relaxation of the abortion pill REMS leaves unclear whether the court would have deferred to the agency’s expertise on the merits. 

female athlete performing high jump
The US Supreme Court abortion pill opinion sets a high bar for FDA lawsuits, but future tests of FDA's authority remain a risk. • Source: Shutterstock

The US Supreme Court’s unanimous decision to dismiss a high-profile case challenging the US Food and Drug Administration’s regulation of the abortion pill mifepristone on the grounds the plaintiff lacked standing set a high bar for future legal challenges of the agency decisions.

Key Takeaways
  • The unanimous Supreme Court ruling in the mifepristone case will limit the types of challenges that can be brought against FDA approval decisions and create some stability and predictability for industry.

But the 13 June ruling does not reassure that the court would defer to the FDA’s expertise and refrain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Business

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By 

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.

Stock Watch: Pfizer Relights Q2 Earnings Season’s Fire

 
• By 

Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.